Publications

Found 1 results
Filters: Author is A. Ardicoglu  [Clear All Filters]
2011
O. A. Uyar, Kara, M., Erol, D., Ardicoglu, A., and Yüce, H., Investigating paraoxonase-1 gene Q192R and L55M polymorphism in patients with renal cell cancer, vol. 10, pp. 133-139, 2011.
Akcay MN, Polat MF, Yilmaz I and Akcay G (2003a). Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 50 (Suppl 2): CCXXV-CCXXVII. PMid:15244186   Akcay MN, Yilmaz I, Polat MF and Akcay G (2003b). Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 50 (Suppl 2): CCLXXIII-CCLXXV. PMid:15244199   Antognelli C, Mearini L, Talesa VN, Giannantoni A, et al. (2005). Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 63: 240-251. http://dx.doi.org/10.1002/pros.20184 PMid:15538743   Azarsiz E and Sonmez EY (2000). Paraoxonase and clinical importance. Turk. J. Biochem. 25: 109-119.   Bonnefont-Rousselot D, Therond P, Beaudeux JL, Peynet J, et al. (1999). High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis. Clin. Chem. Lab. Med. 37: 939-948. http://dx.doi.org/10.1515/CCLM.1999.139 PMid:10616747   Campbell SC (1997). Advances in angiogenesis research: relevance to urological oncology. J. Urol. 158: 1663-1674. http://dx.doi.org/10.1016/S0022-5347(01)64090-4   Chow WH, Devesa SS, Warren JL and Fraumeni JF Jr (1999). Rising incidence of renal cell cancer in the United States. JAMA 281: 1628-1631. http://dx.doi.org/10.1001/jama.281.17.1628 PMid:10235157   Clifford SC, Prowse AH, Affara NA, Buys CH, et al. (1998). Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22: 200-209. http://dx.doi.org/10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#   Connolly JL, Schnitt SJ, Wang HH, Longtine JA, et al. (2003). Principles of Cancer Pathology. In: Cancer Medicine (Kufe DW, Pollock RE and Weichselbaum RR, eds.). Hamilton-BC Decker, London, 487-502.   Durrington PN, Mackness B and Mackness MI (2001). Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 473-480. http://dx.doi.org/10.1161/01.ATV.21.4.473 PMid:11304460   Elkiran ET, Mar N, Aygen B, Gursu F, et al. (2007). Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 7: 48. http://dx.doi.org/10.1186/1471-2407-7-48 PMid:17362500 PMCid:1839096   Gago-Dominguez M and Castelao JE (2006). Lipid peroxidation and renal cell carcinoma: further supportive evidence and new mechanistic insights. Free Radic. Biol. Med. 40: 721-733. http://dx.doi.org/10.1016/j.freeradbiomed.2005.09.026 PMid:16458203   Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, et al. (2002). Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control 13: 287-293. http://dx.doi.org/10.1023/A:1015044518505 PMid:12020111   Hassett C, Richter RJ, Humbert R, Chapline C, et al. (1991). Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 30: 10141-10149. http://dx.doi.org/10.1021/bi00106a010 PMid:1657140   Landis SH, Murray T, Bolden S and Wingo PA (1999). Cancer statistics. CA Cancer J. Clin. 49: 8-31. http://dx.doi.org/10.3322/canjclin.49.1.8 PMid:10200775   Lusini L, Tripodi SA, Rossi R, Giannerini F, et al. (2001). Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma. Int. J. Cancer 91: 55-59. http://dx.doi.org/10.1002/1097-0215(20010101)91:1<55::AID-IJC1006>3.0.CO;2-4   Mackness B, Mackness MI, Arrol S, Turkie W, et al. (1997). Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122: 265-268. http://dx.doi.org/10.1038/sj.bjp.0701390 PMid:9313934 PMCid:1564940   Mackness MI, Arrol S and Durrington PN (1991). Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-154. http://dx.doi.org/10.1016/0014-5793(91)80962-3   Mackness MI, Mackness B, Durrington PN, Connelly PW, et al. (1996). Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7: 69-76. http://dx.doi.org/10.1097/00041433-199604000-00004 PMid:8743898   Playfer JR, Eze LC, Bullen MF and Evans DA (1976). Genetic polymorphism and interethnic variability of plasma paroxonase activity. J. Med. Genet. 13: 337-342. http://dx.doi.org/10.1136/jmg.13.5.337 PMid:1003443 PMCid:1013436   Pljesa-Ercegovac M, Mimic-Oka J, Dragicevic D, Savic-Radojevic A, et al. (2008). Altered antioxidant capacity in human renal cell carcinoma: role of glutathione associated enzymes. Urol. Oncol. 26: 175-181. http://dx.doi.org/10.1016/j.urolonc.2007.02.007 PMid:18312938   Primo-Parmo SL, Sorenson RC, Teiber J and La Du BN (1996). The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33: 498-507. http://dx.doi.org/10.1006/geno.1996.0225 PMid:8661009   Storkel S, Eble JN, Adlakha K, Amin M, et al. (1997). Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 987-989. PMid:9307203   Van Der Logt EM, Janssen CH, Van Hooijdonk Z, Roelofs HM, et al. (2005). No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res. 25: 1465-1470. PMid:15865106   Whang M, O'Toole K, Bixon R, Brunetti J, et al. (1995). The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. J. Urol. 154: 968-970. http://dx.doi.org/10.1016/S0022-5347(01)66945-3